Le Lézard
Classified in: Health

SEX HORMONES, INFLAMMATION AND CANCER


NEW YORK, Oct. 24, 2017 /PRNewswire-iReach/ -- On October 28th, the Endometriosis Foundation of America (endofound.org) is bringing leading medical experts together to examine the relationship between endometriosis and breast and ovarian cancers.   "Breast, Ovary and Endometriosis" is a one-day conference explicitly focusing on the similar behavioral pattern between breast cancer and endometriosis, as they both exhibit uncontrolled, estrogen-dependent proliferation. 

EFA Medical Conference 2017: Breast, Ovary and Endometriosis - October 28, 2017 - Lotte New York Palace Hotel

"In recognition of Breast Cancer Awareness Month our conference will explore the relationship between endometriosis and estrogen at the molecular level and how it relates to an increased risk of both breast and ovarian cancers. Given the success in reducing mortality in breast cancer through early diagnosis and treatment we hope to achieve similar success for endometriosis and ovarian cancer.  By removing the cloud of taboo and mystery about the disease, we can liberate millions of women to live full and meaningful lives including the possibility of having children," said EFA co-founder Tamer Seckin, MD.

Keynote speaker Serdar Bulun, MD., with Northwestern University and Northwestern Memorial Hospital said, "A greater number of ovulatory cycles in a woman significantly increases the risk of endometriosis, ovarian cancer or breast cancer. This strongly suggests a common link between these three key public health problems in the world." 

Bulun will address the dangerous liaisons between steroids and DNA in reproductive tissue.  Dr. Marisa Weiss, MD., founder of Breastcancer.org will discuss the environmental risks of breast cancer and their commonality with endometriosis.

"The breast is a favorite place for cancer to occur in women.  Only 10% of breast cancers are largely due to a single high-risk gene like BRCA1 or 2.  Most are due to a combination of lifestyle, reproductive factors, and environmental exposures," said Weiss.  "This presentation will focus on modifiable risk factors for breast cancer, including several factors that are also associated with endometriosis."

Additional topics slated for discussion include the role of sex hormones in treating endometriosis and their risks, breast cancer in young women, stem cells, fertility preservation, cancer implications for women with endometriosis, and estrogen receptors in both endometriosis and breast cancer.

Presenters joining Drs. Bulun, Seckin and Weiss include Dr. Lisa Halvorson, National Institutes of Health (NIH); Dr. Robert Taylor, Wake Forest School of Medicine;  Dr. Daniela Matei, Northwestern Medicine Feinberg School of Medicine; Drs. Stephanie Falcone Bernick, Karli Goldstein and Jeannine Ann Villella, Lenox Hill Hospital; Dr. Jennifer Knudtson, University of Texas Health & Science Center at San Antonio; Dr. Sarah Berga, Wake Forest Baptist Health; Dr. Michael Nimaroff, Northwell Health; Dr. le Ming Shih, Johns Hopkins Medicine; Dr. Kutluk Oktay, Yale University School of Medicine, Dr. Norbert Gleicher, Center for Human Reproduction; Dr. Monica Halem, New York Dermatologic Surgery Cosmetic Laser Center; and Dr. Harry Reich, best known for pioneering Total Laparoscopic Hysterectomy (TLH).

The conference is at the Lotte New York Palace in Manhattan from 8 am ? 5:30  pm.  Registration is required, and seating is limited. For more information or to register, visit endofound.org/medicalconference or call 646-854-3337.  

The Endometriosis Foundation of America (Endofound.org) was founded by Tamer Seckin, MD, and Padma Lakshmi in 2009 and strives to increase disease recognition, provide advocacy, facilitate expert surgical training, and fund landmark endometriosis research. Engaged in a robust campaign to inform both the medical community and the public, the EFA places particular emphasis on the critical importance of early diagnosis and effective intervention while simultaneously providing education to the next generation of medical professionals and their patients.

BREAST, OVARY & ENDOMETRIOSIS

Where:  Lotte New York Palace. 455 Madison Ave, New York, NY 10022

When:  Saturday, October 28, 2017, 8 am ? 5:30 pm

Details:

Media Contact: Jeanne Rebillard, Endometriosis Foundation Of America, 845.518.4636, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Endometriosis Foundation of America


These press releases may also interest you

at 11:35
SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced that it has received FDA clearance for its novel BowTie Sacroiliac...

at 11:30
SkyQuest projects that the nanotechnology market will attain a value of USD 53.51 billion by 2031, with a CAGR of 36.4% over the forecast period (2024-2031). The increasing demand for nanotechnology in medical research fuels the demand. During...

at 11:30
The Arnold and Mabel Beckman Foundation announced today the selection of its 2024 class of Arnold O. Beckman Postdoctoral Fellows, individuals who underscore the Foundation's mission of supporting basic research in chemical sciences and chemical...

at 11:02
The American College of Clinical Pharmacology® (ACCP) is pleased to announce its 2024 ACCP Annual Meeting (#2024ACCP) will be held September 8 ? 10, 2024. We encourage you to join us for this transformative educational and scientific event! ACCP...

at 11:01
Somavedic, a trailblazer in sleep and digital pollution-neutralizing frequency therapy technology, in collaboration with researchers from the Eye Clinic of Jan Evangelista Purkyn? University and Masaryk Hospital in Ústí nad Labem in the Czech...

at 11:00
The Patient-Centered Outcomes Research Institute (PCORI) today announced the approval of funding awards totaling more than $150 million to support new patient-centered comparative clinical effectiveness research (CER) studies, research to strengthen...



News published on and distributed by: